Centauri Therapeutics
To add a bio or update company history, please click update information.
News from Centauri Therapeutics
Centauri Therapeutics
24 Feb 2026
Centauri Therapeutics secures a £6m Series A extension from AMR Action Fund to target drug-resistant bacterial infections with immunotherapy
Centauri Therapeutics is a biotechnology startup developing immunotherapies using its Alphamer platform. Its treatments are designed to harness the body’s immune response to target infectious diseases, including multidrug-resistant bacteria.
Centauri Therapeutics
29 Jul 2025
Centauri Therapeutics secures a further £3.8m from CARB-X to advance antimicrobial candidate into clinical trials
Centauri Therapeutics develops antimicrobial therapies based on a proprietary immunotherapy platform, with its lead candidate designed to treat serious drug resistant bacterial infections of the lung.
Centauri Therapeutics
- Life Sciences
- Cheshire, United Kingdom
- £9.8m
- centauritherapeutics.com
- Update Information
More venture news
- 2 Mar 2026
Outpost Bio secures a £2.6m pre-seed round led by Merantix Capital and Seedcamp to make human microbiology computable
Pre-seedLife Sciences - 25 Feb 2026
Sonas Pharma secures pre-seed funding led by SFC Capital to develop therapeutics for obesity and epilepsy
Pre-seedLife Sciences - 13 Jan 2026
Allos AI raises £4m in a seed round led by Oxford Science Enterprises to reformulate complex small-molecule generic drugs
SeedLife Sciences
